Abstract 5129
Background
Describe adherence patterns to the medical control processes derived from belonging to a CG situation in a sample of patients in CG situation for hereditary breast and ovarian cancer (CMOH), and its consequences with Psychological Wellbeing.
Methods
Descriptive cross-sectional descriptive study. Participants: Women carriers of high penetrance genes for breast and ovarian cancer (BRCA1 / 2), during the months of July 2012 to May 2014 who continue to control the Hereditary Cancer program of the Català Oncología Institute. 176 women. For the adhesion assessment, 3 asdoca questions were asked, based on recommendations and guidelines, the scale of the psychological well-being (BP) of Ryff was used, validated in the Spanish population.
Results
Regarding breast autoexploration, 58.6% of the patients did not follow the correct follow-up (either by hypervigilance or hypovigilance). Regarding the follow-ups in mammographic controls, 51.4% of the patients do the correct follow-up. When analyzing the relationship between breast self-exploration and the dimensions of psychological well-being, no statistically significant differences were found in any case, the same happens with mammographic controls Regarding the follow-up by MRI, 51.4% of the patients follow the correct one. A relationship is found in the dimension of Autonomy and Purpose in life.
Conclusions
The literature reports that there are well-defined and structured medical treatment protocols that allow monitoring of the carrier patients and that these are understandable to them with the final objective that patients have strategies to manage the situation without uncertainty (Ringwald et al., 2016). One possible explanation is that patients do not fully understand the protocols or that there are other personality variables that are modulating this aspect, such as a passive coping style or a high perception of risk (Den Heijer et al., 2013; Gopie et al., 2012). Conclusions Our population, approximately 50% of patients do not adhere to the proposed follow-up measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melinda Gonzalez Concepcion.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract